Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from China Bozza Development Holdings Limited ( (HK:1069) ).
Shareholders of China Health Technology Group Holding Company Limited approved all resolutions at the 31 December 2025 annual general meeting, including adoption of the 2025 financial statements, director remuneration, reappointment of Jon Gepsom CPA Limited as auditor, and general mandates for the board to issue up to 20% and repurchase up to 10% of the company’s share capital, as well as an extension mandate and the adoption of a new share scheme. The results, all passed by poll with 100% support on votes cast, also confirmed board changes through the re-election or rejection of certain directors and signalled continued support for the company’s capital management flexibility and equity-based incentive arrangements, with implications for future share issuance and governance structure; the company simultaneously disclosed pending changes to the chairman role, board committees and a period of non-compliance with listing rules, underscoring ongoing governance adjustments closely watched by investors.
The most recent analyst rating on (HK:1069) stock is a Hold with a HK$0.46 price target. To see the full list of analyst forecasts on China Bozza Development Holdings Limited stock, see the HK:1069 Stock Forecast page.
More about China Bozza Development Holdings Limited
China Health Technology Group Holding Company Limited, incorporated in the Cayman Islands and listed in Hong Kong (stock code: 1069), operates in the health technology sector. The group focuses on healthcare-related technologies and services within Greater China, positioning itself as a player in the region’s evolving health and medical technology market.
Average Trading Volume: 587,237
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$44.26M
Learn more about 1069 stock on TipRanks’ Stock Analysis page.